NASH

[Acta Pharmacologica Sinica] The authors summarize the latest data of new medications which have completed phase II or III trials for the treatment of nonalcoholic steatohepatitis, and discuss the rationale and preliminary results of several combinatory options.

[Journal of Hepatology] The authors showed that carnitine palmitoyltransferase 1A expression was elevated in hepatic stellate cells of patients with non-alcoholic steatohepatitis, showing a positive correlation with the fibrosis score.

[Journal of Clinical Endocrinology & Metabolism] Investigators focus on the potential role of growth hormone and insulin-like growth factor I in the regulation of hepatic steatosis, inflammation, and fibrosis.

[Axcella Therapeutics] Axcella Therapeutics announced that the US FDA has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.

[Scientific Reports] Researchers identified 130 genes significantly differentially expressed in non-alcoholic steatohepatitis (NASH) versus a mixed group of non-alcoholic fatty liver disease and healthy controls.

[Cancer Gene Therapy] In hepatic cells, Dicer deletion delivered distinct lipid profile and increased lipid oxidation. Mechanically, Dicer deletion caused declined miR-192-3p and increased IGF2 in hepatocytes.